51
|
Valdez KE, Elsarraj HS, Hong Y, Grimm SL, Ricci LR, Fan F, Tawfik O, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Hilsenbeck S, Edwards DP, Hagan C, Godwin AK, Fabian C, Behbod F. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res 2017; 77:3802-3813. [PMID: 28515148 PMCID: PMC8236416 DOI: 10.1158/0008-5472.can-16-2794] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Revised: 03/08/2017] [Accepted: 05/12/2017] [Indexed: 12/16/2022]
Abstract
The beneficial versus detrimental roles of estrogen plus progesterone (E+P) in breast cancer remains controversial. Here we report a beneficial mechanism of E+P treatment in breast cancer cells driven by transcriptional upregulation of the NFκB modulator NEMO, which in turn promotes expression of the tumor suppressor protein promyelocytic leukemia (PML). E+P treatment of patient-derived epithelial cells derived from ductal carcinoma in situ (DCIS) increased secretion of the proinflammatory cytokine IL6. Mechanistic investigations indicated that IL6 upregulation occurred as a result of transcriptional upregulation of NEMO, the gene that harbored estrogen receptor (ER) binding sites within its promoter. Accordingly, E+P treatment of breast cancer cells increased ER binding to the NEMO promoter, thereby increasing NEMO expression, NFκB activation, and IL6 secretion. In two mouse xenograft models of DCIS, we found that RNAi-mediated silencing of NEMO increased tumor invasion and progression. This seemingly paradoxical result was linked to NEMO-mediated regulation of NFκB and IL6 secretion, increased phosphorylation of STAT3 on Ser727, and increased expression of PML, a STAT3 transcriptional target. In identifying NEMO as a pivotal transcriptional target of E+P signaling in breast cancer cells, our work offers a mechanistic explanation for the paradoxical antitumorigenic roles of E+P in breast cancer by showing how it upregulates the tumor suppressor protein PML. Cancer Res; 77(14); 3802-13. ©2017 AACR.
Collapse
Affiliation(s)
- Kelli E. Valdez
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Hanan S. Elsarraj
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Yan Hong
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Sandra L. Grimm
- Department of Molecular & Cellular Biology, Pathology & Immunology, One Baylor Plaza, Houston, Texas 77030
| | - Lawrence R. Ricci
- Department of Radiology, Truman Medical Center, 2301 Holmes Street, Kansas City, MO 64108
| | - Fang Fan
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Ossama Tawfik
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Lisa May
- Department of Radiology, The University of Kansas School of Medicine-Wichita, 1010 N. Kansas, Wichita, KS, 67214
| | - Therese Cusick
- Department of Surgery, The University of Kansas School of Medicine-Wichita, 1010 N. Kansas, Wichita, KS, 67214
| | - Marc Inciardi
- Department of Radiology, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Mark Redick
- Department of Radiology, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Jason Gatewood
- Department of Radiology, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Onalisa Winblad
- Department of Radiology, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Susan Hilsenbeck
- Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030
| | - Dean P. Edwards
- Department of Molecular & Cellular Biology, Pathology & Immunology, One Baylor Plaza, Houston, Texas 77030
| | - Christy Hagan
- Department of Biochemistry, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Andrew K. Godwin
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Carol Fabian
- Department of Medicine, Breast Cancer Survivorship Center, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS, 66160
| | - Fariba Behbod
- Corresponding author and requests for reprints: Fariba Behbod, Department of Pathology and Laboratory Medicine, MS 3045, The University of Kansas Medical Center, Kansas City, KS, 66160, Tel: (913) 945-6642, Fax: (913) 945-6838,
| |
Collapse
|
52
|
Yan XY, Zhang Y, Zhang JJ, Zhang LC, Liu YN, Wu Y, Xue YN, Lu SY, Su J, Sun LK. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Cancer Sci 2017; 108:1405-1413. [PMID: 28498503 PMCID: PMC5497928 DOI: 10.1111/cas.13276] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 05/04/2017] [Accepted: 05/07/2017] [Indexed: 12/21/2022] Open
Abstract
Platinum‐based therapeutic strategies have been widely used in ovarian cancer treatment. However, drug resistance has greatly limited therapeutic efficacy. Recently, tolerance to cisplatin has been attributed to other factors unrelated to DNA. p62 (also known as SQSTM1) functions as a multifunctional hub participating in tumorigenesis and may be a therapeutic target. Our previous study showed that p62 was overexpressed in drug‐resistant ovarian epithelial carcinoma and its inhibition increased the sensitivity to cisplatin. In this study, we demonstrate that the activity of the NF‐κB signaling pathway and K63‐linked ubiquitination of RIP1 was higher in cisplatin‐resistant ovarian (SKOV3/DDP) cells compared with parental cells. In addition, cisplatin resistance could be reversed by inhibiting the expression of p62 using siRNA. Furthermore, deletion of the ZZ domain of p62 that interacts with RIP1 in SKOV3 cells markedly decreased K63‐linked ubiquitination of RIP1 and inhibited the activation of the NF‐κB signaling pathway. Moreover, loss of the ZZ domain from p62 led to poor proliferative capacity and high levels of apoptosis in SKOV3 cells and made them more sensitive to cisplatin treatment. Collectively, we provide evidence that p62 is implicated in the activation of NF‐κB signaling that is partly dependent on RIP1. p62 promotes cell proliferation and inhibits apoptosis thus mediating drug resistance in ovarian cancer cells.
Collapse
Affiliation(s)
- Xiao-Yu Yan
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Yu Zhang
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Juan-Juan Zhang
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Li-Chao Zhang
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Ya-Nan Liu
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Yao Wu
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Ya-Nan Xue
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Sheng-Yao Lu
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Jing Su
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| | - Lian-Kun Sun
- Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China
| |
Collapse
|
53
|
Ma J, Guo W, Li C. Ubiquitination in melanoma pathogenesis and treatment. Cancer Med 2017; 6:1362-1377. [PMID: 28544818 PMCID: PMC5463089 DOI: 10.1002/cam4.1069] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Revised: 03/07/2017] [Accepted: 03/10/2017] [Indexed: 12/13/2022] Open
Abstract
Melanoma is one of the most aggressive skin cancers with fiercely increasing incidence and mortality. Since the progressive understanding of the mutational landscape and immunologic pathogenic factors in melanoma, the targeted therapy and immunotherapy have been recently established and gained unprecedented improvements for melanoma treatment. However, the prognosis of melanoma patients remains unoptimistic mainly due to the resistance and nonresponse to current available drugs. Ubiquitination is a posttranslational modification which plays crucial roles in diverse cellular biological activities and participates in the pathogenesis of various cancers, including melanoma. Through the regulation of multiple tumor promoters and suppressors, ubiquitination is emerging as the key contributor and therefore a potential therapeutic target for melanoma. Herein, we summarize the current understanding of ubiquitination in melanoma, from mechanistic insights to clinical progress, and discuss the prospect of ubiquitination modification in melanoma treatment.
Collapse
Affiliation(s)
- Jinyuan Ma
- Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Weinan Guo
- Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| | - Chunying Li
- Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
| |
Collapse
|
54
|
Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P, Büchler MW, Nachbur U, Neumann UP, Tolba R, Luedde M, Zucman-Rossi J, Panayotova-Dimitrova D, Leverkus M, Preisinger C, Tacke F, Trautwein C, Longerich T, Vucur M, Luedde T. RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell 2017; 31:94-109. [PMID: 28017612 DOI: 10.1016/j.ccell.2016.11.009] [Citation(s) in RCA: 110] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 10/11/2016] [Accepted: 11/15/2016] [Indexed: 12/19/2022]
Abstract
Receptor-interacting protein kinase 1 (RIPK1) represents an essential signaling node in cell death and inflammation. Ablation of Ripk1 in liver parenchymal cells (LPC) did not cause a spontaneous phenotype, but led to tumor necrosis factor (TNF)-dependent hepatocyte apoptosis and liver injury without affecting inducible nuclear factor κB (NF-κB) activation. Loss of Ripk1 induced the TNF-dependent proteasomal degradation of the E3-ligase, TNF receptor-associated factor 2 (TRAF2), in a kinase-independent manner, thereby activating caspase-8. Moreover, loss of both Ripk1 and Traf2 in LPC not only resulted in caspase-8 hyperactivation but also impaired NF-κB activation, promoting the spontaneous development of hepatocellular carcinoma. In line, low RIPK1 and TRAF2 expression in human HCCs was associated with an unfavorable prognosis, suggesting that RIPK1 collaborates with TRAF2 to inhibit murine and human hepatocarcinogenesis.
Collapse
Affiliation(s)
- Anne T Schneider
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany; Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen University, 52074 Aachen, Germany
| | - Jérémie Gautheron
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany; Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen University, 52074 Aachen, Germany
| | - Maria Feoktistova
- Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, Germany
| | | | - Sven H Loosen
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany
| | - Sanchari Roy
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany
| | - Fabian Benz
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany
| | - Peter Schemmer
- Department of Visceral and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany
| | - Markus W Büchler
- Department of Visceral and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany
| | - Ueli Nachbur
- Department of Medical Biology, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Parkville, VIC 3050/3052, Australia
| | - Ulf P Neumann
- Department of Visceral and Transplantation Surgery, RWTH Aachen University, 52074 Aachen, Germany
| | - Rene Tolba
- Department of Laboratory Animal Research, RWTH Aachen University, 52074 Aachen, Germany
| | - Mark Luedde
- Department of Cardiology, University Hospital, 24105 Kiel, Germany
| | | | | | - Martin Leverkus
- Department of Dermatology and Allergology, RWTH Aachen University, 52074 Aachen, Germany
| | | | - Frank Tacke
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany
| | | | - Thomas Longerich
- Department of Pathology, RWTH Aachen University, 52074 Aachen, Germany
| | - Mihael Vucur
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany; Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen University, 52074 Aachen, Germany.
| | - Tom Luedde
- Department of Medicine III, RWTH Aachen University, 52074 Aachen, Germany; Division of Gastroenterology, Hepatology and Hepatobiliary Oncology, RWTH Aachen University, 52074 Aachen, Germany.
| |
Collapse
|
55
|
Seifert L, Miller G. Molecular Pathways: The Necrosome-A Target for Cancer Therapy. Clin Cancer Res 2016; 23:1132-1136. [PMID: 27932417 DOI: 10.1158/1078-0432.ccr-16-0968] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 10/03/2016] [Accepted: 11/02/2016] [Indexed: 12/31/2022]
Abstract
Necroptosis is a caspase-8-independent cell death that requires coactivation of receptor-interacting protein 1 (RIP1) and receptor-interacting protein 3 (RIP3) kinases. The necrosome is a complex consisting of RIP1, RIP3, and Fas-associated protein with death domain leading to activation of the pseudokinase mixed lineage kinase like followed by a rapid plasma membrane rupture and inflammatory response through the release of damage-associated molecular patterns and cytokines. The necrosome has been shown to be relevant in multiple tumor types, including pancreatic adenocarcinoma, melanoma, and several hematologic malignancies. Preclinical data suggest that targeting this complex can have differential impact on tumor progression and that the effect of necroptosis on oncogenesis is cell-type and context dependent. The emerging data suggest that targeting the necrosome may lead to immunogenic reprogramming in the tumor microenvironment in multiple tumors and that combining therapies targeting the necrosome with either conventional chemotherapy or immunotherapy may have beneficial effects. Thus, understanding the interplay of necroptotic cell death, transformed cells, and the immune system may enable the development of novel therapeutic approaches. Clin Cancer Res; 23(5); 1132-6. ©2016 AACR.
Collapse
Affiliation(s)
- Lena Seifert
- Department of General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, University of Dresden, Dresden, Germany
| | - George Miller
- Department of Surgery, S. Arthur Localio Laboratory, New York University School of Medicine, New York, New York. .,Department of Cell Biology, S. Arthur Localio Laboratory, New York University School of Medicine, New York, New York
| |
Collapse
|
56
|
RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. Tumour Biol 2016; 37:15305-15313. [DOI: 10.1007/s13277-016-5342-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 09/06/2016] [Indexed: 01/27/2023] Open
|
57
|
Abstract
Receptor-interacting protein kinase-3 (RIP3, or RIPK3) is an essential protein in the "programmed", or "regulated" necrosis cell death pathway that is activated in response to death receptor ligands and other types of cellular stress. Programmed necrotic cell death is distinguished from its apoptotic counterpart in that it is not characterized by the activation of caspases; unlike apoptosis, programmed necrosis results in plasma membrane rupture, thus spilling the contents of the cell and triggering the activation of the immune system and inflammation. Here we discuss findings, including our own recent data, which show that RIP3 protein expression is absent in many cancer cell lines. The recent data suggests that the lack of RIP3 expression in a majority of these deficient cell lines is due to methylation-dependent silencing, which limits the responses of these cells to pro-necrotic stimuli. Importantly, RIP3 expression may be restored in many cancer cells through the use of hypomethylating agents, such as decitabine. The potential implications of loss of RIP3 expression in cancer are explored, along with possible consequences for chemotherapeutic response.
Collapse
Affiliation(s)
- Michael J Morgan
- Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado, USA
| | - You-Sun Kim
- Department of Biochemistry, Ajou University School of Medicine, 3Department of Biomedical Sciences, Graduate School, Ajou University, Suwon 443-749, Korea
| |
Collapse
|
58
|
ZHU GUANGWEI, YE JIANXIN, HUANG YONGJIAN, ZHENG WEI, HUA JIN, YANG SHUGANG, ZHUANG JINFU, WANG JINZHOU. Receptor-interacting protein-1 promotes the growth and invasion in gastric cancer. Int J Oncol 2016; 48:2387-98. [DOI: 10.3892/ijo.2016.3455] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Accepted: 02/23/2016] [Indexed: 11/06/2022] Open
|
59
|
Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol 2016; 37:8849-56. [PMID: 26749282 DOI: 10.1007/s13277-015-4762-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 12/29/2015] [Indexed: 12/26/2022] Open
Abstract
Receptor-interacting protein kinase 1 (RIP1K) and RIP3K belong to RIPK family, which regulate cell survival and cell death. In the present investigation, the expression levels of RIP1K and RIP3K were evaluated in the 30 malignant, 15 benign, and 20 normal breast tissues, and their correlation with clinicopathological characteristics was also studied. The expression levels of RIP1K and RIP3K were determined, by western blot analysis. The relative RIP1K expression was significantly higher in the malignant and benign tumors when compared to those of normal tissues (P < 0.0001 and P < 0.001, respectively). However, the expression level of RIP3K was significantly lower in the malignant tumors than those of normal and benign values (P < 0.001 and P < 0.01, respectively). Positive significant correlation was found for RIP1K expression with tumor size (P < 0.001), grades (P < 0.0001), and c-erbB2 (P < 0.001), but negative significant correlation was detected with patient's age (P < 0.001), estrogen receptor (ER) (P < 0.001), progesterone receptor (PR) (P < 0.01), and P53 (P<0.01) status. RIP3K expression was significantly lower in the pre-menopauses (P < 0.01), grade III (P < 0.05), ER-negative (P < 0.05), and c-erbB2-negative malignant tumors, but no correlation was detected with tumor size, PR, and P53 status. No significant correlation was observed for RIP1K and RIP3K expressions with Ki67 and Her2. Based on the present results, it is concluded that reduction of RIP3K expression in the malignant breast tumor might be an important evidence to support the antitumor activity of this enzyme in vivo. However, RIP1K expression was shown to be higher in the malignant breast tumors than those of normal and benign breast tissues, which probably designates as a poor prognostic factor.
Collapse
|
60
|
Jin L, Chen J, Liu XY, Jiang CC, Zhang XD. The double life of RIPK1. Mol Cell Oncol 2015; 3:e1035690. [PMID: 27308554 DOI: 10.1080/23723556.2015.1035690] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Revised: 03/25/2015] [Accepted: 03/26/2015] [Indexed: 01/08/2023]
Abstract
We have recently identified receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIPK1) as an oncogenic driver in melanoma in addition to its well-established role in controlling cell survival and death. Our studies show that RIPK1 promotes melanoma cell proliferation through a positive feedback loop of NFKB1-BIRC2/BIRC3-RIPK1 powered by autocrine tumor necrosis factor.
Collapse
Affiliation(s)
- Lei Jin
- School of Medicine and Public Health, The University of Newcastle , NSW, Australia
| | - Jiezhong Chen
- School of Biomedical Sciences and Pharmacy, The University of Newcastle , NSW, Australia
| | - Xiao Ying Liu
- School of Biomedical Sciences and Pharmacy, The University of Newcastle, NSW, Australia; School of Life Science, Anhui Medical University, Anhui, China
| | - Chen Chen Jiang
- School of Medicine and Public Health, The University of Newcastle , NSW, Australia
| | - Xu Dong Zhang
- School of Biomedical Sciences and Pharmacy, The University of Newcastle , NSW, Australia
| |
Collapse
|